Back to top Open menu arrow
Download PDF Reprints

The Journal of
Clinical Psychiatry
Members only

Original Research Focus on Women’s Mental Health December 15, 2025

Valproic Acid Use Trends, Patterns, and Predictors in Females of Reproductive Age in the United States

; ; ; ;

J Clin Psychiatry 2026;87(1):25m16009

Abstract

Objective: To provide an up-to-date evaluation of valproic acid (VPA) use trends, patterns, and predictors in females of reproductive age in ambulatory care settings in the US.

Methods: A retrospective, cross-sectional study was conducted using 2017 through 2022 Medical Expenditure Panel Survey data to examine trends in VPA use. Prescription rates were calculated per 1,000 prescription events with 95% confidence intervals. VPA prescriptions were stratified by clinical indication and recipient group (females aged 12–49 years, females aged ≥50 years, and males aged 12–49 years). Multivariable logistic regression was used to identify predictors of VPA use among females aged 12–49 years and all females with comorbid bipolar disorder, headache, or seizure conditions.

Results: The cumulative total of VPA prescription events across the 2017–2022 study period was 29,754,849 (95% CI, 23,843,243–35,666,455). Of these, 5,442,682 (95% CI, 2,879,340–8,006,024) were issued to females aged 12–49 years (18.3% of all VPA prescriptions). From 2017 to 2022, VPA prescribing decreased by nearly 50% (P =.037). Most VPA prescriptions filled by females aged 12–49 years were for migraine or other headache syndromes (27.2%), followed by bipolar disorder (24.6%) and convulsions or epilepsy (20.7%). Of the estimated 153,120 females aged 12–49 years who filled a prescription for VPA between 2017–2022, 85.9% were not using contraception.

Conclusion: Approximately 1 in 5 VPA prescriptions between 2017 to 2022 were prescribed to females of reproductive age. VPA was most commonly used for the treatment of migraine or other headache syndrome, followed by bipolar disorder and convulsive disorder. Only 14.1% of females of reproductive age using VPA were also using contraception. Interventional studies aimed at reducing VPA use in females of reproductive age are needed.

J Clin Psychiatry 2026;87(1):25m16009

Author affiliations are listed at the end of this article.

Members Only Content

This full article is available exclusively to Professional tier members. Subscribe now to unlock the HTML version and gain unlimited access to our entire library plus all PDFs. If you’re already a subscriber, please log in below to continue reading.

Subscribe Now

Already a member? Log in

  1. Gotlib D, Ramaswamy R, Kurlander JE, et al. Valproic acid in women and girls of childbearing age. Curr Psychiatry Rep. 2017;19(9):58. PubMed CrossRef
  2. Tomson T, Battino D, Bromley R, et al. Executive summary: management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epilepsia. 2019;60(12):2343–2345. PubMed CrossRef
  3. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–252. PubMed CrossRef
  4. Romoli M, Mazzocchetti P, D’Alonzo R, et al. Valproic acid and epilepsy: from molecular mechanisms to clinical evidences. Curr Neuropharmacol. 2019;17(10):926–946. PubMed CrossRef
  5. Food and Drug Administration. FDA Drug Safety Communication: Valproate Anti-seizure Products Contraindicated for Migraine Prevention in Pregnant Women due to Decreased IQ Scores in Exposed Children. 2013. Accessed June 23, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-valproate-anti-seizure-products-contraindicated-migraine-prevention#:∼:text=%5B05%2D06%2D2013%5D,the%20prevention%20of%20migraine%20headaches
  6. World Health Organization. Statement on the risks associated with use of valproic acid (sodium valproate) in women and girls of childbearing potential. 2023. Accessed June 23, 2025. https://www.who.int/news/item/02-05-2023-use-of-valproic-acid-in-women-and-girls-of-childbearing-potential
  7. Freeman MP. Prescribing Guideline for valproic acid and women of reproductive potential: forget it exists. J Clin Psychiatry. 2022;83(6):22ed14609. PubMed CrossRef
  8. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170. PubMed CrossRef
  9. Ghosh S, Sinha JK, Khan T, et al. Pharmacological and therapeutic approaches in the treatment of epilepsy. Biomedicines. 2021;9(5):470. PubMed CrossRef
  10. Vatzaki E, Straus S, Dogne JM, et al. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. J Headache Pain. 2018;19(1):68. PubMed CrossRef
  11. Rizvi A, Shaan F, Reyazuddin M. Valproate prescribed to reproductive-age women in ambulatory care: analysis of 2018-2019 National Ambulatory Health Care data. Prim Care Companion CNS Disord. 2023;25(4):22br03500. PubMed CrossRef
  12. Birnbaum AK. Are women of childbearing Age still receiving valproate? Epilepsy Curr. 2018;18(6):380–381. PubMed CrossRef
  13. Gaudio M, Konstantara E, Joy M, et al. Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study. BMC Pregnancy Childbirth. 2022;22(1):73. PubMed CrossRef
  14. Andrade C, Jyothi SA, Renitha T, et al. Use of valproate in women: an audit of prescriptions to 10,001 psychiatry, neurology, and neurosurgery outpatients. J Clin Psychiatry. 2021;83(1):21m14023. PubMed CrossRef
  15. Clavenna A, Campi R, Putignano D, et al. Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy. Br J Clin Pharmacol. 2022;88(3):1152–1158. PubMed CrossRef
  16. Di Vito L, Mazzoni S, Belotti LMB, et al. Impact of regulatory restrictions on the use of valproic acid in women of childbearing age: an Italian study. Epilepsia. 2023;64(4):910–918. PubMed CrossRef
  17. Scholz K, Köster I, Meyer I, et al. Prescribing of valproate and oral antiepileptics for women of childbearing age and during pregnancy in Germany between 2010 and 2020. Pharmacoepidemiol Drug Saf. 2023;32(11):1306–1314. PubMed CrossRef
  18. Ura H, Matsuoka N, Kubota K, et al. Trends in prescription of anti-seizure medications in Japan between 2018 and 2021: a retrospective study using the National Database Open Data Japan. Epilepsy Behav. 2024;159:109949. PubMed CrossRef
  19. Hughes JE, Buckley N, Looney Y, et al. Valproate utilisation trends among women of childbearing potential in Ireland between 2014 and 2019: a drug utilisation study using interrupted time series. Pharmacoepidemiol Drug Saf. 2022;31(6):661–669. PubMed CrossRef
  20. Tennant M, Frampton C, Mulder R, et al. Changes in sodium valproate dispensing in women of childbearing age with a diagnosis of borderline personality disorder in Aotearoa New Zealand. N Z Med J. 2024;137(1597):36–43. PubMed CrossRef
  21. Corfe-Tan J, McLay L, Mentzel C. Prescription of sodium valproate to women of childbearing potential in Southern District Mental Health Services in New Zealand. Australas Psychiatry. 2023;31(6):776–781. PubMed CrossRef
  22. Wójcik K, Kruk M, Koń B, et al. Treatment patterns in women of childbearing age and pregnant women with epilepsy in Poland between the years 2019 and 2022-A nationwide population-based cohort study. Seizure. 2024;115:75–80. PubMed CrossRef
  23. Degremont A, Kerbrat S, Balusson F, et al. Prescribing trends for valproate among pregnant women: a cross-sectional study in 2013 and 2016 using the French Health Insurance Database. Neurology. 2022;98(21):e2163–e2173. PubMed CrossRef
  24. Kurvits K, Laius O, Uusküla M, et al. Valproic acid prescription trends among females of childbearing age in Estonia: a 14-year nationwide prescription database study. Seizure. 2020;76:28–31. PubMed CrossRef
  25. Agency for Healthcare Research and Quality. MEPS HC 243 2022 Full Year Consolidated Data File. 2024. Accessed June 23, 2025. https://www.meps.ahrq.gov/data_stats/download_data/pufs/h243/h243doc.pdf
  26. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey, Survey Background. Accessed June 23, 2025. https://www.meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp
  27. Agency for Healthcare Research and Quality. MEPS HC 239A: 2022 Prescribed Medicines. 2024. Accessed June 23, 2025. https://www.meps.ahrq.gov/data_stats/download_data/pufs/h239a/h239adoc.pdf
  28. Agency for Healthcare Research and Quality. MEPS HC 241: 2022 Medical Conditions. 2024. Accessed June 23, 2025. https://www.meps.ahrq.gov/data_stats/download_data/pufs/h241/h241doc.pdf
  29. Smolinski NE, Sarayani A, Thai TN, et al. Prenatal exposure to valproic acid across various indications for use. JAMA Netw Open. 2024;7(5):e2412680. PubMed CrossRef
  30. Valentino K, Teopiz KM, Kwan ATH, et al. Anatomical, behavioral, and cognitive teratogenicity associated with valproic acid: a systematic review. CNS Spectr. December 2024;29(6):604–610. PubMed CrossRef
  31. Hird MA, Sandoe CH. Migraine management in medically complex patients: a narrative review. Curr Neurol Neurosci Rep. 2024;24(9):423–438. PubMed CrossRef
  32. European Medicines Agency. Valproate and related substances. 2018. Accessed June 23, 2025. https://www.ema.europa.eu/en/news/new-measures-avoid-valproate-exposure-pregnancy-endorsed
  33. Daniels K, Abma JC. Current Contraceptive Status Among Women Aged 15–49: United States, 2017–2019. NCHS Data Brief;2020(388):1–8. PubMed
  34. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016;374(9):843–852. PubMed CrossRef
  35. The New York Times. Tracking the States Where Abortion Is Now Banned. 2022. Accessed June 23, 2025. https://www.nytimes.com/interactive/2022/us/abortion-laws-roe-v-wade.html
  36. Sarayani A, Albogami Y, Thai TN, et al. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies. Am J Obstet Gynecol. 2022;227(2):263.e1–263.e38. PubMed CrossRef
  37. Adedinsewo DA, Thurman DJ, Luo YH, et al. Valproate prescriptions for nonepilepsy disorders in reproductive-age women. Birth Defects Res A Clin Mol Teratol. 2013;97(6):403–408. PubMed CrossRef
  38. Wisner KL, Leckman-Westin E, Finnerty M, et al. Valproate prescription prevalence among women of childbearing age. Psychiatr Serv. 2011;62(2):218–220. PubMed CrossRef
  39. Colas S, Nishikawa T, Dresco I, et al. Effectiveness of the additional risk minimisation measures for valproate among healthcare professionals and Patients: a Cross-Sectional Survey in six European countries. Pharmacoepidemiol Drug Saf. 2024;33(11):e70046. PubMed CrossRef
  40. Hill CE, Lin CC, Suresh S, et al. Perceptions of reproductive risk among women with epilepsy of childbearing age. Epilepsy Behav. 2024;161:110107. PubMed CrossRef
  41. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes. Stat Med. 2019;38(7):1276–1296. PubMed CrossRef
  42. Precision Standards Guidelines for Reporting MEPS-HC Descriptive Statistics. Accessed August 5, 2025. https://meps.ahrq.gov/survey_comp/precision_guidelines.shtml

About the Authors

Buy PDF for $40

Please sign in or purchase this PDF for $40.

Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Postpartum Distress in Women With and Without ADHD

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

In Memoriam

In Memoriam: Terence A. Ketter, MD

Narrative Review

Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice

Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
View current Issue

Consensus Report on XT Use in Practice

Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe